FDA Takes Regulatory Action against Ranbaxy India Plant

The Food and Drug Administration recently announced that a facility owned by India-based Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. The facility, Paonta Sahib, has been under an FDA Import Alert since September 2008.

FDA is continuing to investigate this matter to ensure the safety and efficacy of marketed drugs associated with Ranbaxy's Paonta Sahib site. To date, FDA has no evidence that these drugs do not meet their quality specifications and has not identified any health risks associated with currently marketed Ranbaxy products.

"The FDA's investigations revealed a pattern of questionable data raising significant questions regarding the reliability of certain applications, and this warrants applying the Application Integrity Policy," said Deborah Autor, director of CDER's Office of Compliance. "Today's action reflects the FDA's continued vigilance and its steadfast commitment to safeguarding the public's health."

In the meantime, FDA recommends that patients not disrupt their drug therapy because this could jeopardize their health. Individuals who are concerned about their medications should talk with their health care professional.

The affected applications are for drugs that fall into three categories:

  • Approved drugs made at the Paonta Sahib site for the U.S. market;
  • Drugs pending approval at the FDA that are not yet marketed; and
  • Certain drugs manufactured in the United States that relied on data from the Paonta Sahib facility.

"Companies must provide truthful and accurate information in their marketing applications," said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research (CDER). "The American public expects and deserves no less."

To address the falsified data, FDA has invoked its Application Integrity Policy (AIP) against the Paonta Sahib facility. AIP is invoked when a company's actions raise significant questions about the integrity of data in drug applications. This AIP covers applications that rely on data generated by the Paonta Sahib facility only.

Under the AIP, FDA has asked Ranbaxy to cooperate with the agency to resolve the questions of data integrity and reliability. This would include implementing a Corrective Action Operating Plan (CAOP) to provide assurance of the integrity and reliability of data from the Paonta Sahib facility. A CAOP includes, but is not limited to, conducting a third-party independent audit of applications associated with Paonta Sahib.

When the AIP is implemented, FDA stops all substantive scientific review of any new or pending drug approval applications that contain data generated by the Paonta Sahib facility.

On Sept. 16, 2008, the FDA issued two warning letters and instituted an Import Alert barring the entry of all finished drug products and active pharmaceutical ingredients from Ranbaxy's Dewas, Paonta Sahib and Batamandi Unit facilities due to violations of United States current Good Manufacturing Practices requirements. That action barred the commercial importation of 30 different generic drugs into the United States and remains in effect.

Download Center

HTML - No Current Item Deck
  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Steps to Conduct a JSA

    We've put together a comprehensive step-by-step guide to help you perform a job safety analysis (JSA), which includes a pre-built, JSA checklist and template, steps of a JSA, list of potential job hazards, and an overview of hazard control hierarchy.

  • Everything You Need to Know about Incident investigations

    Need some tips for conducting an incident investigation at work after there’s been an occupational injury or illness, or maybe even a near miss? This guide presents a comprehensive overview of methods of performing incident investigations to lead you through your next steps.

  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January February 2021

    January February 2021

    Featuring:

    • TRAINING: SOFTWARE
      Tips for Choosing the Best Training Software
    • COMBUSTIBLE DUST
      Assessing the Dangers of Dust Explosions
    • HAND PROTECTION
      Pushing the Boundaries of Hand Protection
    • FOOT PROTECTION
      Getting a Grip on Slip Resistance
    View This Issue